Suchen
Nuvalent Inc
NUVLZur Watchlist hinzufügen
102.300USD
-2.110-2.02%
Handelsschluss 05/15, 16:00（ET）Kurse um 15 Minuten verzögert
8.08BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Nuvalent Inc Unternehmen
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
Nuvalent Inc Informationen
BörsenkürzelNUVL
Name des UnternehmensNuvalent Inc
IPO-datumJul 29, 2021
CEOPorter (James R)
Anzahl der mitarbeiter142
WertpapierartOrdinary Share
GeschäftsjahresendeJul 29
AddresseOne Broadway, 14Th Floor
StadtCAMBRIDGE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02142
Telefon18573577000
Websitehttps://www.nuvalent.com/
BörsenkürzelNUVL
IPO-datumJul 29, 2021
CEOPorter (James R)
Führungskräfte von Nuvalent Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.59M
-0.37%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
65.60K
--
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
44.43K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
17.02K
--
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+51.44%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.50K
-5.92%
Dr. Michael L. Meyers, M.D., Ph.D.
Dr. Michael L. Meyers, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.50K
-5.92%
Dr. James R. (Jim) Porter, Ph.D.
Dr. James R. (Jim) Porter, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Christopher D. Turner, M.D.
Dr. Christopher D. Turner, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Deborah Miller, J.D., Ph.D.
Dr. Deborah Miller, J.D., Ph.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.59M
-0.37%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
65.60K
--
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
44.43K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
17.02K
--
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+51.44%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.50K
-5.92%
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, May 10
Aktualisiert: Sun, May 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Deerfield Management Company, L.P.
23.45%
Fidelity Management & Research Company LLC
14.19%
Paradigm BioCapital Advisors LP
7.16%
BlackRock Institutional Trust Company, N.A.
5.04%
Vanguard Portfolio Management, LLC
3.40%
Andere
46.76%
Aktionäre
Aktionäre
Anteil
Deerfield Management Company, L.P.
23.45%
Fidelity Management & Research Company LLC
14.19%
Paradigm BioCapital Advisors LP
7.16%
BlackRock Institutional Trust Company, N.A.
5.04%
Vanguard Portfolio Management, LLC
3.40%
Andere
46.76%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
43.62%
Hedge Fund
38.79%
Investment Advisor/Hedge Fund
21.04%
Individual Investor
2.77%
Venture Capital
2.58%
Private Equity
2.26%
Research Firm
1.46%
Sovereign Wealth Fund
0.78%
Bank and Trust
0.33%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
490
86.91M
118.14%
+5.88M
2025Q4
462
75.27M
104.86%
-2.57M
2025Q3
440
73.50M
109.27%
-4.34M
2025Q2
438
75.09M
113.13%
-1.35M
2025Q1
443
75.23M
113.38%
-1.51M
2024Q4
428
73.56M
111.20%
-2.43M
2024Q3
401
72.99M
113.51%
-264.12K
2024Q2
367
68.27M
114.85%
-2.37M
2024Q1
344
66.52M
113.46%
-4.79M
2023Q4
296
66.77M
116.76%
+1.56M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Deerfield Management Company, L.P.
17.25M
23.57%
-742.57K
-4.13%
Dec 31, 2025
Fidelity Management & Research Company LLC
10.44M
14.27%
+685.62K
+7.03%
Dec 31, 2025
Paradigm BioCapital Advisors LP
5.27M
7.2%
--
--
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
3.71M
5.06%
+578.29K
+18.49%
Dec 31, 2025
Wellington Management Company, LLP
2.46M
3.36%
+160.96K
+7.00%
Dec 31, 2025
T. Rowe Price Associates, Inc.
2.10M
2.86%
+330.62K
+18.74%
Dec 31, 2025
JP Morgan Asset Management
2.01M
2.75%
+498.40K
+32.96%
Dec 31, 2025
RA Capital Management, LP
1.88M
2.57%
+633.60K
+50.83%
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
Tema Oncology ETF
4.14%
ALPS Medical Breakthroughs ETF
2.65%
Global X Guru Index ETF
1.57%
State Street SPDR S&P Biotech ETF
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
iShares Health Innovation Active ETF
0.82%
Direxion Daily S&P Biotech Bull 3X Shares
0.72%
ProShares Ultra Nasdaq Biotechnology
0.65%
Invesco Nasdaq Biotechnology ETF
0.64%
iShares Biotechnology ETF
0.39%
Mehr Anzeigen
Tema Oncology ETF
Anteil4.14%
ALPS Medical Breakthroughs ETF
Anteil2.65%
Global X Guru Index ETF
Anteil1.57%
State Street SPDR S&P Biotech ETF
Anteil1.16%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.86%
iShares Health Innovation Active ETF
Anteil0.82%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.72%
ProShares Ultra Nasdaq Biotechnology
Anteil0.65%
Invesco Nasdaq Biotechnology ETF
Anteil0.64%
iShares Biotechnology ETF
Anteil0.39%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
